MegaPro Biomedical Co., Ltd. engages in the development of drug ingredients related to nanoparticles and nanocell technology platforms. Its products include iron agent for iron deficiency in chronic kidney diseases, contrast agent for liver and lymph nodes magnetic resonance imaging, and anti-cancer drugs. The company was founded on November 7, 2014 and is headquartered in Hsinchu, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company